NO20100584L - Fremgangsmate ved bruk av HPLC for a male mengden 5-(2-kloretyl)-1,3-dihydro-2H-indol-on i et preparat omfattende 6-klor-5-(2-kloretyl)-1,3 dihydro-2H-indol-2-on - Google Patents

Fremgangsmate ved bruk av HPLC for a male mengden 5-(2-kloretyl)-1,3-dihydro-2H-indol-on i et preparat omfattende 6-klor-5-(2-kloretyl)-1,3 dihydro-2H-indol-2-on

Info

Publication number
NO20100584L
NO20100584L NO20100584A NO20100584A NO20100584L NO 20100584 L NO20100584 L NO 20100584L NO 20100584 A NO20100584 A NO 20100584A NO 20100584 A NO20100584 A NO 20100584A NO 20100584 L NO20100584 L NO 20100584L
Authority
NO
Norway
Prior art keywords
chloroethyl
dihydro
indolone
hplc
chloro
Prior art date
Application number
NO20100584A
Other languages
English (en)
Inventor
Frank Robert Busch
Jr Harry Ralph Howard
Adam Worth Grobin
Kyle Robert Leeman
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27761437&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20100584(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Publication of NO20100584L publication Critical patent/NO20100584L/no
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Liquid Crystal Substances (AREA)
  • Indole Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Pyridine Compounds (AREA)

Abstract

Det beskrives en fremgangsmåte ved bruk av HPLC for å måle mengden 5-(2-kloretyl)-1,3-dihydro-2H-indol-on i et preparat omfattende 6-klor-5-(2-kloretyl)-1,3-dihydro-2H-indol-2-on.
NO20100584A 2002-02-20 2010-04-22 Fremgangsmate ved bruk av HPLC for a male mengden 5-(2-kloretyl)-1,3-dihydro-2H-indol-on i et preparat omfattende 6-klor-5-(2-kloretyl)-1,3 dihydro-2H-indol-2-on NO20100584L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US35880602P 2002-02-20 2002-02-20
US35903802P 2002-02-21 2002-02-21
US36045902P 2002-02-27 2002-02-27
PCT/IB2003/000642 WO2003070246A1 (en) 2002-02-20 2003-02-17 Controlled synthesis of ziprasidone and compositions thereof

Publications (1)

Publication Number Publication Date
NO20100584L true NO20100584L (no) 2004-09-17

Family

ID=27761437

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20043902A NO20043902L (no) 2002-02-20 2004-09-17 Kontrollert syntese av ziprasidon og sammensetninger derav
NO20100584A NO20100584L (no) 2002-02-20 2010-04-22 Fremgangsmate ved bruk av HPLC for a male mengden 5-(2-kloretyl)-1,3-dihydro-2H-indol-on i et preparat omfattende 6-klor-5-(2-kloretyl)-1,3 dihydro-2H-indol-2-on

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO20043902A NO20043902L (no) 2002-02-20 2004-09-17 Kontrollert syntese av ziprasidon og sammensetninger derav

Country Status (41)

Country Link
EP (1) EP1476162B1 (no)
JP (1) JP4554938B2 (no)
KR (1) KR100773622B1 (no)
CN (2) CN101735212A (no)
AP (1) AP2004003103A0 (no)
AR (1) AR038563A1 (no)
AT (1) ATE359787T1 (no)
AU (2) AU2003206035A1 (no)
BR (1) BR0307833A (no)
CA (1) CA2475302C (no)
CO (1) CO5611138A2 (no)
CY (1) CY1106467T1 (no)
DE (1) DE60313289T2 (no)
DK (1) DK1476162T3 (no)
EA (1) EA007866B1 (no)
EC (1) ECSP045239A (no)
ES (1) ES2283745T3 (no)
GE (1) GEP20074030B (no)
GT (1) GT200300040A (no)
HR (1) HRP20040711A2 (no)
IL (1) IL163277A (no)
IS (1) IS7344A (no)
MA (1) MA27177A1 (no)
MX (1) MXPA04006993A (no)
MY (1) MY139523A (no)
NO (2) NO20043902L (no)
NZ (1) NZ534443A (no)
OA (1) OA12774A (no)
PA (1) PA8567001A1 (no)
PE (1) PE20030942A1 (no)
PL (1) PL372238A1 (no)
PT (1) PT1476162E (no)
RS (1) RS60404A (no)
SI (1) SI1476162T1 (no)
SV (1) SV2004001485A (no)
TN (1) TNSN04159A1 (no)
TW (1) TW200307546A (no)
UA (1) UA77057C2 (no)
UY (1) UY27668A1 (no)
WO (1) WO2003070246A1 (no)
ZA (1) ZA200406276B (no)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100879647B1 (ko) 2000-03-06 2009-01-20 아카디아 파마슈티칼스 인코포레이티드 세로토닌 관련 질병의 치료에 사용되는 아자시클릭 화합물
NZ533567A (en) 2001-12-28 2007-06-29 Acadia Pharm Inc Spiroazacyclic compounds as monoamine receptor for modulating 5-HT2A receptor-mediated events
US7538222B2 (en) 2002-06-24 2009-05-26 Acadia Pharmaceuticals, Inc. N-substituted piperidine derivatives as serotonin receptor agents
US7253186B2 (en) 2002-06-24 2007-08-07 Carl-Magnus Andersson N-substituted piperidine derivatives as serotonin receptor agents
JP2005533813A (ja) 2002-06-24 2005-11-10 アカディア ファーマシューティカルズ，インコーポレーテッド セロトニン受容体作用物質としてのｎ−置換ピペリジン誘導体
US7488729B2 (en) 2002-12-04 2009-02-10 Dr. Reddy's Laboratories Limited Polymorphic forms of ziprasidone and its hydrochloride salt and process for preparation thereof
WO2004050655A1 (en) * 2002-12-04 2004-06-17 Dr. Reddy's Laboratories Limited Polymorphic forms of ziprasidone and its hydrochloride
ATE407117T1 (de) 2003-01-16 2008-09-15 Acadia Pharm Inc Selektive serotonin 2a/2c inverse rezeptoragonisten als therapeutika für neurodegenerative erkrankungen
US7199144B2 (en) 2003-04-21 2007-04-03 Teva Pharmaceuticals Industries, Ltd. Process for the preparation of valsartan and intermediates thereof
DE602004013405T2 (de) 2003-03-17 2009-05-07 Teva Pharmaceutical Industries Ltd. Polymorphe formen von valsartan
EP1618097A1 (en) 2003-04-21 2006-01-25 Teva Pharmaceutical Industries Ltd Process for the preparation of valsartan
US7678799B2 (en) 2003-06-03 2010-03-16 Teva Pharmaceutical Industries Ltd. Crystalline ziprasidone HCl and processes for preparation thereof
CA2543805A1 (en) 2003-10-24 2005-05-06 Gideon Pilarsky Processes for preparation of ziprasidone
JP2007514001A (ja) * 2003-12-18 2007-05-31 テバ ファーマシューティカル インダストリーズ リミティド ジプラシドン塩基の多形形態ｂ２
ATE451367T1 (de) * 2004-02-27 2009-12-15 Ranbaxy Lab Ltd Verfahren zur herstellung von ziprasidon
CA2467538C (en) 2004-05-14 2010-08-24 Apotex Pharmachem Inc. New amorphous ziprasidone hydrochloride (5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one hydrochloride) and processes to produce the same
US7820695B2 (en) 2004-05-21 2010-10-26 Acadia Pharmaceuticals, Inc. Selective serotonin receptor inverse agonists as therapeutics for disease
CA2471219A1 (en) 2004-06-14 2005-12-14 Apotex Pharmachem Inc. Improved preparation of an anhydrate form of 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one hydrochloride (ziprasidone hydrochloride)
CN101031548B (zh) 2004-09-27 2011-04-06 阿卡蒂亚药品公司 N-(4-氟苄基)-n-(1-甲基哌啶-4-基)-n'-(4-(2-甲基丙氧基)-苯基甲基)脲的盐及其制备
US7790899B2 (en) 2004-09-27 2010-09-07 Acadia Pharmaceuticals, Inc. Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms
ES2250000B1 (es) * 2004-09-29 2007-06-01 Medichem, S.A. Procedimiento para la preparacion de ziprasidona.
ES2250001B1 (es) * 2004-09-29 2007-06-01 Medichem, S.A. Proceso para la purificacion de ziprasidona.
WO2006080025A1 (en) * 2005-01-27 2006-08-03 Hetero Drugs Limited Process for ziprasidone using novel intermediates
ITMI20052216A1 (it) * 2005-11-18 2007-05-19 Dipharma Spa Procedimento per la preparazione di ziprasidone
CN100491375C (zh) * 2006-07-01 2009-05-27 浙江美诺华药物化学有限公司 一种齐拉西酮的制备方法
WO2008116024A2 (en) 2007-03-19 2008-09-25 Acadia Pharmaceuticals Inc. Combinations of 5-ht2a inverse agonists and antagonists with antipsychotics
CN102234272A (zh) * 2010-04-21 2011-11-09 上海医药工业研究院 盐酸齐拉西酮半水合物的制备方法
CN102234273B (zh) * 2010-04-21 2015-08-05 上海医药工业研究院 甲磺酸齐拉西酮半水合物及其制备方法
CN107848972B (zh) 2015-07-20 2021-06-18 阿卡蒂亚药品公司 用于制备n-(4-氟苄基)-n-(1-甲基哌啶-4-基)-n’-(4-(2-甲基丙氧基)苯基甲基)脲及其酒石酸盐和多晶型c的方法
WO2017165635A1 (en) 2016-03-25 2017-09-28 Acadia Pharmaceuticals Inc. Combination of pimavanserin and cytochrome p450 modulators
US10953000B2 (en) 2016-03-25 2021-03-23 Acadia Pharmaceuticals Inc. Combination of pimavanserin and cytochrome P450 modulators
EP3558311A1 (en) 2016-12-20 2019-10-30 Acadia Pharmaceuticals Inc. Pimavanserin alone or in combination for use in the treatment of alzheimer's disease psychosis
CN108239085A (zh) * 2016-12-26 2018-07-03 四川科瑞德凯华制药有限公司 一种甲磺酸齐拉西酮的纯化及制备方法
WO2018200977A1 (en) 2017-04-28 2018-11-01 Acadia Pharmaceuticals Inc. Pimavanserin for treating impulse control disorder
WO2019046167A1 (en) 2017-08-30 2019-03-07 Acadia Pharmaceuticals Inc. PIMAVANSERIN FORMULATIONS
CN112724066B (zh) * 2021-02-04 2022-10-21 海南鑫开源医药科技有限公司 一种盐酸齐拉西酮中间体中的二卤杂质及其制备方法
CN116046966A (zh) * 2023-01-17 2023-05-02 北京协和建昊医药技术开发有限责任公司 一种流动相配置装置及其配置方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4831031A (en) 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
US5206366A (en) 1992-08-26 1993-04-27 Pfizer Inc. Process for preparing aryl piperazinyl-heterocyclic compounds
US5338846A (en) * 1992-08-26 1994-08-16 Pfizer Inc. Process for preparing aryl piperazinyl-heterocyclic compounds with a piperazine salt
US5312925A (en) * 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
US5359068A (en) * 1993-06-28 1994-10-25 Pfizer Inc. Processes and intermediates for the preparation of 5-[2-(4-(benzoisothiazol-3-yl)-piperazin-1-yl)ethyl]-6-chloro-1,3-dihydro-indol-2-one
DE69611253T2 (de) 1995-11-07 2001-04-05 Pfizer Inc., New York Verfahren und zwischenprodukte für die herstellung von 3-(1-piperazinyl)-1,2-benzisothiazolen
TR199802241T2 (no) * 1996-05-07 1999-02-22 Pfizer Inc.
TW491847B (en) 1996-05-07 2002-06-21 Pfizer Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one
IL127497A (en) * 1997-12-18 2002-07-25 Pfizer Prod Inc Medicinal products containing piperazinyl-heterocyclic compounds for the treatment of psychiatric disorders
US6150366A (en) * 1998-06-15 2000-11-21 Pfizer Inc. Ziprasidone formulations

Also Published As

Publication number Publication date
TW200307546A (en) 2003-12-16
DK1476162T3 (da) 2007-07-02
GEP20074030B (en) 2007-02-12
BR0307833A (pt) 2004-12-07
CN101735212A (zh) 2010-06-16
CO5611138A2 (es) 2006-02-28
GT200300040A (es) 2007-01-12
EP1476162A1 (en) 2004-11-17
PE20030942A1 (es) 2003-11-08
MXPA04006993A (es) 2004-11-10
PT1476162E (pt) 2007-06-25
CA2475302C (en) 2009-05-12
EA007866B1 (ru) 2007-02-27
CN1635892A (zh) 2005-07-06
NZ534443A (en) 2007-07-27
IL163277A (en) 2010-05-31
ECSP045239A (es) 2004-09-28
NO20043902L (no) 2004-09-17
EP1476162B1 (en) 2007-04-18
MY139523A (en) 2009-10-30
CY1106467T1 (el) 2012-01-25
TNSN04159A1 (fr) 2007-03-12
SI1476162T1 (sl) 2007-08-31
JP4554938B2 (ja) 2010-09-29
DE60313289T2 (de) 2007-12-27
CA2475302A1 (en) 2003-08-28
KR20040086417A (ko) 2004-10-08
UY27668A1 (es) 2003-10-31
AU2009202008A1 (en) 2009-06-11
ES2283745T3 (es) 2007-11-01
DE60313289D1 (de) 2007-05-31
RS60404A (sr) 2006-10-27
KR100773622B1 (ko) 2007-11-05
JP2005525347A (ja) 2005-08-25
PL372238A1 (en) 2005-07-11
PA8567001A1 (es) 2003-12-10
EA200400815A1 (ru) 2004-12-30
AP2004003103A0 (en) 2004-09-30
HRP20040711A2 (en) 2004-12-31
WO2003070246A1 (en) 2003-08-28
AR038563A1 (es) 2005-01-19
IS7344A (is) 2004-07-05
ZA200406276B (en) 2005-09-20
SV2004001485A (es) 2004-05-07
ATE359787T1 (de) 2007-05-15
UA77057C2 (en) 2006-10-16
AU2003206035A1 (en) 2003-09-09
OA12774A (en) 2006-07-04
MA27177A1 (fr) 2005-01-03

Similar Documents

Publication Publication Date Title
WO2004013120A8 (en) Novel benzodioxoles
MX2009002229A (es) Benzotriazoles como moduladores de cinasas.
ATE384058T1 (de) Thiazolderivate
WO2007130075A8 (en) Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors
WO2010036998A3 (en) Indole and indoline derivatives and methods of use thereof
DE59510635D1 (de) Verwendung heterocyclischer verbindungen als dopamin-d 3 liganden
LU91758I2 (fr) Denosumab et ses dérivés pharmaceutiquement acceptables (PROLIA®)
NO20071974L (no) Blodplate-avledet vekstfaktor sammensetning og fremgangsmater for anvendelse derav
NO20075809L (no) DNA-PK inhibitorer
PE20130239A1 (es) Compuestos heteroaril-aril-ureas como inhibidores de la quinasa
NO20054082L (no) Pyrazol`1,5-A! 1,3,5! triazinderivater som kannabinoidreseptorligander
NO2010020I1 (no) 5-{{4-[(2,3-dimetyl-2H-indazot-6-yl)(metyl)amino]pyrimidin-2-yl}amino)-2-metylbenzensulfonamid Pazopanib.
NO20054404L (no) 5,7-Diaminopyrazolo [4,3-D] Pyrimidiner Anvendelige ved behandling av of Hypertensjon
TW200600111A (en) Improved dental whitening method
TR200000014T2 (tr) Yeni ikameli imidazol bileşimleri.
NO20082939L (no) Sykloheksyl piperasinyl metanon derivater og anvendelse av disse som histamin H3 reseptor modulatorer
NO20075361L (no) Fremgangsmate og preparat for behandling av slimhinneforstyrrelser
NZ509378A (en) Amorphous ammonium salts of eprosartan and pharmaceuticals thereof, useful for blocking angiotensin II receptors and useful for treating hypertension, congestive heart disease and renal failure
MX2008013040A (es) Derivados de bencimidazol 5-sulfonamida como ligandos del receptor cannabinoide 1.
MXPA05007115A (es) Nuevos agonistas inversos del receptor cb 1.
ATE477256T1 (de) Thienylverbindungen
AR038563A1 (es) Composicion de ziprasidona y controles sinteticos
NO20052529L (no) Forbindelse og sammensetning, og anvendelse av samme
BR0317708A (pt) Composto, composição farmacêutica, e, uso de um composto
WO2005075450A3 (en) Spiro-benzodioxoles and their use as cb1 antagonists

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application